ArticleElectrophoresis2012
High-capacity peptide-centric platform to decode the proteomic response to brain injury.
Article in Electrophoresis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects.Frontiers in neurology · 2023Review
- Serum peptidome: diagnostic window into pathogenic processes following occupational exposure to carbon nanomaterials.Particle and fibre toxicology · 2021Article
- Pulmonary delivery of the broad-spectrum matrix metalloproteinase inhibitor marimastat diminishes multiwalled carbon nanotube-induced circulating bioactivity without reducing pulmonary inflammation.Particle and fibre toxicology · 2021Article
- Traumatic Brain Injury Temporal Proteome Guides KCC2-Targeted Therapy.Journal of neurotrauma · 2019Article
- Nanoparticle exposure driven circulating bioactive peptidome causes systemic inflammation and vascular dysfunction.Particle and fibre toxicology · 2019Article
- Article
- Current and Emerging Technologies for Probing Molecular Signatures of Traumatic Brain Injury.Frontiers in neurology · 2017Review
- Current status of fluid biomarkers in mild traumatic brain injury.Experimental neurology · 2016Review
- Proteomics: in pursuit of effective traumatic brain injury therapeutics.Expert review of proteomics · 2015Review
- Post-acute brain injury urinary signature: a new resource for molecular diagnostics.Journal of neurotrauma · 2014Article
- Systems biology approaches for discovering biomarkers for traumatic brain injury.Journal of neurotrauma · 2013Review
- Exposure of rats to environmental tobacco smoke during cerebellar development alters behavior and perturbs mitochondrial energetics.Environmental health perspectives · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Traumatic brain injury (TBI) is a progressive disease process underlain by dynamic and interactive biochemical mechanisms; thus, large-scale and unbiased assessments are needed to fully understand its highly complex pathobiology. Here, we report on a new high-capacity label-free proteomic platform to evaluate the post-TBI neuroproteome. Six orthogonal separation stages and data-independent MS were employed, affording reproducible quantitative assessment on 18 651 peptides across biological replicates. From these data 3587 peptides were statistically responsive to TBI of which 18% were post-translationally modified. Results revealed as many as 484 proteins in the post-TBI neuroproteome, which was fully nine times the number determined from our prior study of focal cortical injury. Yet, these data were generated using 25 times less brain tissue per animal relative to former methodology, permitting greater anatomical specificity and proper biological replication for increased statistical power. Exemplified by these data, we discuss benefits of peptide-centric differential analysis to more accurately infer novel biological findings testable in future hypothesis-driven research. The high-capacity label-free proteomic platform is designed for multi-factor studies aimed at expanding our knowledge on the molecular underpinnings of TBI and to develop better diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.